Mylan launches generic Adcirca in U.S. for pulmonary arterial hypertension

Mylan N.V. (MYL +1%) commences the U.S. commercial launch of its generic version of Eli Lilly’s (LLY +0.1%) Adcirca (tadalafil) for patients with pulmonary arterial hypertension.

Per IQVIA, the U.S. market is ~$510M.

https://bit.ly/BHqASL